BioSpace News Archive

Event to go LIVE at 1pm (ET) on 3/15/2019 with participation from iconic brands

PepsiCo’s Former Vice Chairman and Chief Scientific Officer, Former President of Global R&D, Takeda Pharmaceuticals, to Lead Longevity Biotech

Huntington Hospital announced the retirement of Paul L. H. Ouyang as chairman of its board of directors, effective March 31, 2019.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that results from the Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, have been selected for oral presentation during a featured clinical research session at the American College of Cardiology’s 68th Annual Scientific Session

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced the appointment of Richard A. van den Broek to its board of directors, effective February 27, 2019.

Indoor air quality- whether home, school or office- may not immediately, or secondarily, come to mind as a carcinogenic source. Still, elevated indoor radon levels remain the second leading cause of lung cancer today according to medical associations and government agencies, including the AMA and EPA.

Heron Therapeutics, Inc. announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 39th Annual Cowen Healthcare Conference on Monday, March 11, 2019, at 2:10 p.m. EST at The Boston Marriott Copley Place.

Medical device industry leaders to focus on blockchain technology, M&A trends and federal policy

New study led by NEEKA Health Canada will test if CBD-based therapies can reduce the severity of post-concussion brain disorders in former NHL players

Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of a new extended dosing schedule for KEYTRUDA®, Merck’s anti-PD-1 therapy, for all approved monotherapy indications in the European Union.